Myriad Genetics (MYGN) saw its stock surge 5.02% in pre-market trading on Thursday, following the announcement of 11 new research studies to be presented at the upcoming National Society of Genetic Counselors (NSGC) 44th Annual Conference. This significant pre-market movement reflects investor optimism about the company's advancements in genetic testing technology and its potential impact on future growth.

The studies, set to be presented on November 7 and 8, 2025, will showcase Myriad Genetics' latest developments across various genetic testing products. These include the MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen, and Foresight® Carrier Screen. The research topics span a wide range, covering RNA analysis in hereditary cancer testing, advancements in prenatal screening, and professional development for genetic counselors.

This announcement demonstrates Myriad Genetics' commitment to innovation and its strong position in the competitive genetic testing market. The positive pre-market reaction suggests that investors are anticipating these research findings to potentially lead to new product developments or improvements, which could strengthen the company's market position and drive future revenue growth. As the conference approaches, market participants will likely keep a close eye on the outcomes of these presentations and their potential implications for Myriad Genetics' business prospects.